Literature DB >> 7538603

Expressions of E-cadherin and exon v6-containing isoforms of CD44 and their prognostic values in human transitional cell carcinoma.

R L Hong1, Y S Pu, T S Hsieh, J S Chu, W J Lee.   

Abstract

Cell surface adhesion molecules, E-cadherin and exon v6 containing CD44 isoforms (CD44v6), were readily found in well-to-moderately differentiated urothelial cell lines but were down-regulated in poorly differentiated cell lines. One hundred and fifteen tumors of transitional cell carcinoma (TCC) were examined with E-cadherin and CD44v6 specific antibodies. Sixty-five (56.5%) tumors exhibited a preserved type while 50 (43.5%) showed a reduced type for CD44v6. Sixty-seven (58.3%) tumors were classified as the preserved type, and 48 (41.7%) were classified as the reduced type for E-cadherin. The staining pattern of E-cadherin was the same as that of CD44v6 in 87.0% (100 of 115) of tumors. The frequency of the reduced type was higher in poorly differentiated carcinomas (32 of 52 for CD44v6, p = 0.001; 27 of 52 for E-cadherin, p = 0.112) and tumors with an invasive growth pattern (22 of 27 for CD44v6, p < 0.001; 20 of 27 for E-cadherin, p < 0.001) than it was in well-differentiated carcinomas and tumors with expansile growth. However, the association with lymph node involvement or distant metastasis did not reach statistical significance. There was no difference in survival in reference to the expression patterns of CD44v6 and E-cadherin. Furthermore, neither marker was a significant prognostic factor for tumor recurrence and survival according to Cox's multiple variant regression analysis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7538603

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  8 in total

1.  Progressive loss of CD44 gene expression in invasive bladder cancer.

Authors:  T Sugino; H Gorham; K Yoshida; J Bolodeoku; V Nargund; D Cranston; S Goodison; D Tarin
Journal:  Am J Pathol       Date:  1996-09       Impact factor: 4.307

2.  Focal loss of CD44 variant protein expression is related to recurrence in superficial bladder carcinoma.

Authors:  V Toma; D Hauri; U Schmid; D Ackermann; R Maurer; G Alund; H Knönagel; M Rist; T C Gasser; G Sauter; J Roth
Journal:  Am J Pathol       Date:  1999-11       Impact factor: 4.307

3.  Pathological function of prostaglandin E2 receptors in transitional cell carcinoma of the upper urinary tract.

Authors:  Yasuyoshi Miyata; Kojiro Ohba; Shigeru Kanda; Koichiro Nomata; Jiro Eguchi; Tomayoshi Hayashi; Hiroshi Kanetake
Journal:  Virchows Arch       Date:  2006-04-12       Impact factor: 4.064

4.  CD44 standard form expression as a predictor of progression in high risk superficial bladder tumors.

Authors:  N E Stavropoulos; I Filliadis; E Ioachim; M Michael; E Mermiga; K Hastazeris; U O Nseyo
Journal:  Int Urol Nephrol       Date:  2001       Impact factor: 2.370

5.  Relationship of PCNA, C-erbB2 and CD44s expression with tumor grade and stage in urothelial carcinomas of the bladder.

Authors:  Ayhan Yıldırım; Mustafa Kösem; Ilyas Sayar; Ibrahim Gelincik; Alparslan Yavuz; Aliseydi Bozkurt; Unal Erkorkmaz; Irfan Bayram
Journal:  Int J Clin Exp Med       Date:  2014-06-15

6.  [Use of silicon chip technology to detect protein-based tumor markers in bladder cancer].

Authors:  T Jäger; T Szarvas; F vom Dorp; C Börgermann; M Schenck; K W Schmid; H Rübben
Journal:  Urologe A       Date:  2007-09       Impact factor: 0.639

7.  Effect of CD44 gene polymorphisms on risk of transitional cell carcinoma of the urinary bladder in Taiwan.

Authors:  Wei-Chun Weng; Yu-Hui Huang; Shun-Fa Yang; Shian-Shiang Wang; Wu-Hsien Kuo; Chao-Wen Hsueh; Ching-Hsuan Huang; Ying-Erh Chou
Journal:  Tumour Biol       Date:  2015-12-12

8.  The adhesion molecule CD44v6 is associated with a high risk for local recurrence in adult soft tissue sarcomas.

Authors:  S Maula; R L Huuhtanen; C P Blomqvist; T A Wiklund; P Laurila; R Ristamäki
Journal:  Br J Cancer       Date:  2001-01       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.